tachycardia semaglutide Weight loss drug reduces risk of adverse cardiovascular events by 20% among overweight, obese patients GLP-1 Agonists and Heart Rate

Due to its robust glucose-lowering capacity and convenient once-weekly dosing, tirzepatide represents a significant advancement in the therapeutic landscape of T2DM

IQVIA blog, December 2024: GLP-1s and digital support: A winning combination

Kids 12 years and older with an initial body mass index at or above the 95th percentile for age and sex (based on growth charts) can use semaglutide

FDA Approves First New Molecular Entity Under National Priority Voucher Program

[1] This dual effect helps improve glycemic control without causing significant hypoglycemia in most patients, though the risk increases when combined with insulin or sulfonylureas